Monoclonal Antibody

Category

NIAID ACTIV-3 Study Investigating LY-CoV555 & Remdesivir Placed on Pause: Drug Safety Monitoring Board Move Based on Safety Concern

The ACTIV-3 clinical trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and a large group of collaborators, has been paused due to possible safety issues observed by the independent data safety monitoring board (DSMB). This federally...

Lilly, NIAID & Care Access Research Transform How Studies Done to Reach Nursing Homes During COVID-19 Pandemic

On Aug. 3, TrialSite applauded the effort of  Lilly & Co. (NYSE: LLY) and the National Institute of Allergy and Infectious Diseases (NIAID) for the Blaze-2 clinical trial. Why? Because it’s one of the first, if not the first nationwide intervention during the...

Lilly on the Verge of COVID-19 Monoclonal Antibody EUA Approval First for High Risk Patients with Recent Mild-to-Moderate COVID-19 Diagnosis

TrialSite shared that Eli Lilly’s (Lilly) monoclonal antibody program targeting COVID-19 appeared to be working, at least according to some trial site reports. Now Lilly is moving to secure an emergency use authorization for its monotherapy (LY-CoV555) to the U.S....

ACTIV-2 Clinical Trial Comes to University of Pittsburgh School of Medicine: Investigators Test LY-CoV555 & Potentially Ab8

The University of Pittsburgh School of Medicine (Pitt) represents one of 25 initiated trial site organizations investigating novel therapies targeting the earlier stages of COVID-19 in a bid to start focusing on early treatment to reduce disease progression. Pitt has...

Trial Site Operation in San Antonio Reports Positive Momentum for Regeneron Monoclonal Antibody REGN-COV-2

TrialSite has reported that Lilly's monoclonal antibody (LY-CoV555) evidenced promise at a trial site location in southern Texas and that shortly thereafter recent interim analysis data from Lilly backed that observation. Now Regeneron’s monoclonal antibody cocktail...

Lilly’s Monoclonal Antibody Produces Positive Data, Company Gears up for Further Review & Inks Production Deal with Amgen

TrialSite News reported on Aug 22 that a South Texas trial site location reported growing confidence in a SARS-CoV-2 neutralizing antibody-based investigational product developed by Eli Lilly (Lilly) called LY-CoV555. Developed with the help of powerful discovery...

Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19

TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program. Now, local media (WSYX/WTTE) reports that the Columbus-based site...

Oxford RECOVERY Trial Investigates Regeneron’s REGN-COV2: Will it Reduce Mortality, Hospital Stay & Need for Ventilation?

The prominent global RECOVERY (Randomized Evaluation of COVid-19 thERapY) is one of the world’s largest randomized clinical trials of potential COVID-19 treatments. It was this study that discovered the benefit of dexamethasone in severe COVID-19 cases. The University...

Pin It on Pinterest